Minerva Neurosciences | NERV - Ebitda


Minerva Neurosciences reported $-4.36M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Adma Biologics USD 73.59M 14.85M Dec/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cipla INR 9.55B 3B Mar/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
J&J USD 7.19B 2.32B Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Takeda JPY 150.25B 297.88B Mar/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024